MarketPulse

povetacicept

2 articles
The Motley FoolThe Motley Fool··Adria Cimino

Vertex Pharma's $600 Target Hinges on Diversification Beyond Cystic Fibrosis

Vertex Pharmaceuticals eyes 25% stock upside to $600 as it expands beyond cystic fibrosis with new drug approvals and kidney disease candidate povetacicept.
VRTXbiotechrevenue growth
BenzingaBenzinga··Vandana Singh

Vertex's Kidney Drug Povetacicept Wins Pivotal Trial, Shares Jump 6%+

$VERX surges 6.3% after kidney drug povetacicept achieves Phase 3 trial success with 52% proteinuria reduction, positioning FDA approval by year-end.
VRTXIBBBBHFDA approvalclinical development